CUDC-101 is a small-molecule inhibitor that targets histone deacetylases (HDACs), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor receptor 2 tyrosine kinase (HER2/ErbB2). As a hybrid dual-acting inhibitor, it not only blocks these receptors but also reduces compensatory pathways such as AKT, HER3, and MET. CUDC-101 shows potential in suppressing various tumor progressions. Reagent grade, for research purpose.
Usually ships within 24 hours.